利妥昔单抗联合化疗治疗非霍奇金淋巴瘤疗效的Meta分析

摘要/Abstract

摘要： 目的：系统评价利妥昔单抗联合化疗治疗非霍奇金淋巴瘤（non-hodgkin′s lymphoma， NHL）的临床疗效，为临床用药及药物政策提供参考。方法：计算机检索中英文数据库1998～2014年间公开发表的利妥昔单抗联合与单用化疗治疗NHL的随机或临床对照试验（RCT、CCT）文献。结果：治疗组与对照组完全缓解率CR （RR=1.35，95%CI[1.22，1.49]）、3年总生存率（RR=1.30，95%CI[1.03，1.65]）有显著性差异；但5年总生存率（RR=1.45，95%CI[0.83，2.53]）无显著差异。结论：Meta分析结果表明，利妥昔单抗联合化疗治疗NHL比单纯化疗完全缓解率、3年总生存率更高。

Abstract: Objective： The study is to provide reference for clinical use and drug policy through systematically evaluating the clinical efficacy of the combined use of rituximab and chemotherapy in the treatment of non-hodgkin′s lymphoma (NHL). Methods： Literatures of the randomized or clinical controlled trial on the combined use of rituximab and chemotherapy in the treatment of NHL are retrieved in the international and domestic online databases from 1998 to 2014.Results： Meta-analysis showed that the complete remission rate {RR=1.35，95%CI[1.22，1.49]}、 3-year overall survival rate {RR=1.30，95%CI[1.03，1.65]} of experimental group and the control group were statistically different， but 5-year overall survival rate {RR=1.45，95%CI[0.83，2.53]} of the experimental group and the control group was not statistically different. Conclusion： Current results indicated that the application of rituximab for the treatment of NHL provided a high level of complete remission rate and 3-year overall survival rate.

李倩,马爱霞. 利妥昔单抗联合化疗治疗非霍奇金淋巴瘤疗效的Meta分析[J]. .

参考文献

[1] Fabrizio Marcucci, Alfonso Mele. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities [J].American Society Of Hematology,2011,117(6).
[2] 任金马.恶性淋巴瘤的流行病学研究进展[J].南通医学院学报,2003,23(4).
[3]阎骅,沈志祥.非霍奇金淋巴瘤靶点治疗及其临床应用前景[J].内科理论与实践,2009,4(1).
[4] 董国贤,姚文庆,黎均耀.沈阳地区恶性淋巴瘤发病因素的研究[J].实用肿瘤学杂志,1988, 2(4): 268.
[5]中华医学会血液学分会.中国弥漫大B细胞诊断与治疗指南.2013.
[6]中华医学会血液学分会.中国滤泡性淋巴瘤诊断与治疗指南.2013.
[7]Gross S A, Zhu X Z, Bao L, et al. A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. Int J Hematol, 2008, 88(22): 165-173.
[8] Matthew C Winter, B W Hancock .Ten years of rituximab in NHL, Expert Opinion on Drug Safety,SMarch 2009, 8(2): 223-235.
[9]NCCN非霍奇金淋巴瘤临床实践指南(中国版).2010.1.
[10]NCCN.org. NCCN Clinical Practice Guidelines in Oncology(Non-Hodgkin’s Lymphoma), Version 1.2013.
[11]利妥昔单抗注射液说明书.2010.5.21修改.
[12]李旸,刘卓刚,郝良纯等.中国非霍奇金淋巴瘤患者行利妥昔单抗联合CHOP方案化疗疗效与安全性的 Meta分析.循证医学,2011, 11(2): 112-116.
[13]徐同成,李霞,王文亮等.分类变量Meta分析中偏倚的检测—Egger法和Begg法[J].循证医学,2009,9(3):181-184.
[14] 吴守华,俞晓娟,王小龙.CHOP联合美罗华治疗B细胞性非霍奇金淋巴瘤的临床研究[J].淮海医药,2010,28(6).
[15]张敬宇,杨琳,罗建民等. R-CHOP方案与CHOP方案治疗初治弥漫性大B细胞淋巴瘤的临床对比研究[J].第一届难治性淋巴瘤学术研讨会暨第二节全国多发性骨髓瘤学术研讨会继续教育集:109.
[16]林桐榆,张红雨,黄岩等. R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症, 2005,24(12):1421-1426.
[17]彭鹏,邹文蓉,王瑜. R-CHOP与CHOP方案治疗生发中心和非生发中心来源DLBCL疗效评价[J].现代医药卫生,2013,29(16).
[18]洪斌,王婉茹,孙宏伟. 利妥昔单抗辅助治疗B细胞非霍奇金淋巴瘤32例疗效评估[J].疑难病杂志,2012,11(9).
[19]郭丽堃,黎民君,罗华山等. 利妥昔单抗联合CHOP方案治疗B细胞型非霍奇金淋巴瘤的疗效评价[J].肿瘤药学,2012,2(2).
[20]郭俊煜,石浩强,张芬琴等. 利妥昔单抗联合CHOP方案治疗NHL的临床疗效评价[J].中国药房,2007,18(26).
[21]王秋萍,赵立峰. 利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤16例[J].河北医药,2008,30(11).
[22]闫秀云. 利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤临床研究[J].中国医刊,2012,47(3).
[23]苏坤.利妥昔单抗联合CHOP化疗方案治疗CD20阳性B细胞性非霍奇金淋巴瘤疗效观察[J].临床合理用药,2012,5(8A).
[24]龚雪迪. 美罗华联合CHOP方案治疗B细胞性非霍奇金淋巴瘤的临床研究[J].当代医学,2012,18(18).
[25]曾爱屏,于起涛,周韶璋等. 美罗华联合CHOP方案指标弥漫大B细胞淋巴瘤对的疗效观察[J].2013,5(2).
[26]双跃荣,叶大茜,陈建祥等. 美罗华联合CHOP方案治疗侵袭性B细胞淋巴瘤45例临床疗效观察[J].中国肿瘤临床,2007,34(24).
[27]梁春林,崔建东,张羽等. 美罗华联合CHOP方案治疗侵袭性B细胞淋巴瘤临床观察[J].实用临床医药杂志,2010,14(9).
[28]王彦华,蔡华,翁香勤等. CHOP方案单用或联合美罗华治疗48例弥漫大B细胞淋巴瘤的随机对照临床研究[J].中国综合临床,2006,22(11).
[29] Michael Pfreundschuh, Joerg Schubert, Marita Ziepert et.al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 B-cell lymphomas: a randomised controlled trial (RICOVER-60) [J]. The lancet,2008,9.
[30] Michael Pfreundschuh, Joerg Schubert, Marita Ziepert et.al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 B-cell lymphomas: a randomised controlled trial (RICOVER-60) [J]. The lancet,2008,9.
[31] Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste et.al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy patients: a study by the Groupe d’Etudes des Lymphomes del’Adulte in DLBCL [J]. Blood,2010,116,2040-2045.
[32] P. Feugier, A. Van Hoof, C. Sebban et.al. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe'Etude desLymphomes del'Adulte [J]. Journal of clinical oncology,2005,23(18).
[33]Thomas P.Miller, M.D., Steve Dahlberg et.al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade Non-hodgkin’s lymphoma [J]. The New England Journal of Medicine,2012,339(1).
[34]Bertrand Coiffier, M.D., Eric Lepage et.al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. The New England Journal of Medicine,2002,346(4).
[35] Wolfgang Hiddemann, Michael Kneba, Martin Dreyling et.al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J]. Blood, 2005,106: 3725-3732.
[36] Thomas M. Habermann, Edie A. Weller, Vicki A. Morrison et.al. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma [J]. Journal of clinical oncology, 2006,24(19).
[37] Bertrand Coiffier. Rituximab in Combination With CHOP Improves Survival inElderly Patients With Aggressive Non-Hodgkin’s Lymphoma [J]. Seminars in Oncology,2002,29(2).
[38] Robert Marcus, Kevin Imrie, Philippe Solal-Celigny et.al. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma [J]. Journal of clinical oncology,2008,26(28).
[39] Roswitha Forstpointner, Martin Dreyling, Roland Repp et.al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group[J].Blood, 2004,104: 3064-3071.
[40] Michael Herold, Antje Haas, Stefanie Srock et.al. Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study [J], Journal of clinical oncology,2007,25(15).